Biomedical Research

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 504 6082390

Research Article - Biomedical Research (2017) Volume 28, Issue 8

Pyrazinamide resistance in MDR and extensively drug-resistant tuberculosis

Background: Pyrazinamide (PZA) is an important first-line antituberculosis drug in drug resistant and drug sensitive regimen. Incorporation of pyrazinamide into the first-line regimen had made it possible to reduce the treatment duration to six months. But drug resistant rate of PZA is high in MDR and XDR tuberculosis.

Methods: We reviewed a phase II clinical trial in our hospital to identify the clinical characteristics of PZA resistant tuberculosis.

Results: In our study, the mean time of anti-tuberculosis treatment before enrolled in the study was 2.6 ± 3.1 years in the PZA resistant (PZAr) group and 2.3 ± 1.4 years in the PZA sensitive (PZAs) group. The mean time of using PZA prior to the study in PZAr group and PZAs group were 1.1 ± 2.0 years and 0.5 ± 0.3 years respectively. The rate of PZA resistance was 80% (16/20) in MDR-TB and 100% (7/7) in XDR-TB.

Conclusions: So whether to use PZA in MDR or XDR tuberculosis regimen still needs be identified.

Author(s): Lan Yao, Qing Zhang, Yidan Liu, Heping Xiao

Abstract Full Text PDF